39 related articles for article (PubMed ID: 16443723)
1. Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses.
Lu Y; Riddell D; Hajos-Korcsok E; Bales K; Wood KM; Nolan CE; Robshaw AE; Zhang L; Leung L; Becker SL; Tseng E; Barricklow J; Miller EH; Osgood S; O'Neill BT; Brodney MA; Johnson DS; Pettersson M
J Pharmacol Exp Ther; 2012 Aug; 342(2):366-75. PubMed ID: 22562771
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer's Disease.
Pettersson M; Johnson DS; Humphrey JM; Am Ende CW; Butler TW; Dorff PH; Efremov IV; Evrard E; Green ME; Helal CJ; Kauffman GW; Mullins PB; Navaratnam T; O'Donnell CJ; O'Sullivan TJ; Patel NC; Stepan AF; Stiff CM; Subramanyam C; Trapa P; Tran TP; Vetelino BC; Yang E; Xie L; Pustilnik LR; Steyn SJ; Wood KM; Bales KR; Hajos-Korcsok E; Verhoest PR
J Med Chem; 2024 Jun; ():. PubMed ID: 38848667
[TBL] [Abstract][Full Text] [Related]
3. New precision medicine avenues to the prevention of Alzheimer's disease from insights into the structure and function of γ-secretases.
De Strooper B; Karran E
EMBO J; 2024 Mar; 43(6):887-903. PubMed ID: 38396302
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibitors of the PSEN1-gamma-secretase complex.
Serneels L; Narlawar R; Perez-Benito L; Municoy M; Guallar V; T'Syen D; Dewilde M; Bischoff F; Fraiponts E; Tresadern G; Roevens PWM; Gijsen HJM; De Strooper B
J Biol Chem; 2023 Jun; 299(6):104794. PubMed ID: 37164155
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis for isoform-selective inhibition of presenilin-1 by MRK-560.
Guo X; Wang Y; Zhou J; Jin C; Wang J; Jia B; Jing D; Yan C; Lei J; Zhou R; Shi Y
Nat Commun; 2022 Oct; 13(1):6299. PubMed ID: 36272978
[TBL] [Abstract][Full Text] [Related]
6. Active site geometry stabilization of a presenilin homolog by the lipid bilayer promotes intramembrane proteolysis.
Feilen LP; Chen SY; Fukumori A; Feederle R; Zacharias M; Steiner H
Elife; 2022 May; 11():. PubMed ID: 35579427
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
8. Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects.
Toyn JH; Boy KM; Raybon J; Meredith JE; Robertson AS; Guss V; Hoque N; Sweeney F; Zhuo X; Clarke W; Snow K; Denton RR; Zuev D; Thompson LA; Morrison J; Grace J; Berisha F; Furlong M; Wang JS; Lentz KA; Padmanabha R; Cook L; Wei C; Drexler DM; Macor JE; Albright CF; Gasior M; Olson RE; Hong Q; Soares HD; AbuTarif M; Ahlijanian MK
J Pharmacol Exp Ther; 2016 Jul; 358(1):125-37. PubMed ID: 27189974
[TBL] [Abstract][Full Text] [Related]
9. Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β.
Toyn JH; Ahlijanian MK
Alzheimers Res Ther; 2014; 6(2):14. PubMed ID: 25031632
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Characterization of a Novel γ-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects.
Hyde LA; Zhang Q; Del Vecchio RA; Leach PT; Cohen-Williams ME; Chen L; Wong GT; McHugh NA; Chen J; Higgins GA; Asberom T; Li W; Pissarnitski D; Levitan D; Nomeir AA; Clader JW; Zhang L; Parker EM
Int J Alzheimers Dis; 2013; 2013():823528. PubMed ID: 23573456
[TBL] [Abstract][Full Text] [Related]
11. The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat.
Tai LM; Jacobsen H; Ozmen L; Flohr A; Jakob-Roetne R; Caruso A; Grimm HP
J Pharmacokinet Pharmacodyn; 2012 Jun; 39(3):227-37. PubMed ID: 22481485
[TBL] [Abstract][Full Text] [Related]
12. Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.
Basi GS; Hemphill S; Brigham EF; Liao A; Aubele DL; Baker J; Barbour R; Bova M; Chen XH; Dappen MS; Eichenbaum T; Goldbach E; Hawkinson J; Lawler-Herbold R; Hu K; Hui T; Jagodzinski JJ; Keim PS; Kholodenko D; Latimer LH; Lee M; Marugg J; Mattson MN; McCauley S; Miller JL; Motter R; Mutter L; Neitzel ML; Ni H; Nguyen L; Quinn K; Ruslim L; Semko CM; Shapiro P; Smith J; Soriano F; Szoke B; Tanaka K; Tang P; Tucker JA; Ye XM; Yu M; Wu J; Xu YZ; Garofalo AW; Sauer JM; Konradi AW; Ness D; Shopp G; Pleiss MA; Freedman SB; Schenk D
Alzheimers Res Ther; 2010 Dec; 2(6):36. PubMed ID: 21190552
[TBL] [Abstract][Full Text] [Related]
13. BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.
Marks N; Berg MJ
Neurochem Res; 2010 Feb; 35(2):181-210. PubMed ID: 19760173
[TBL] [Abstract][Full Text] [Related]
14. Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer's disease.
Iqbal K; Chohan MO; Grundke-Iqbal I
J Alzheimers Dis; 2008 Oct; 15(2):339-45. PubMed ID: 18953118
[TBL] [Abstract][Full Text] [Related]
15. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.
Aluise CD; Sowell RA; Butterfield DA
Biochim Biophys Acta; 2008 Oct; 1782(10):549-58. PubMed ID: 18760351
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention.
Iqbal K; Grundke-Iqbal I
J Cell Mol Med; 2008; 12(1):38-55. PubMed ID: 18194444
[TBL] [Abstract][Full Text] [Related]
17. Developing pharmacological therapies for Alzheimer disease.
Iqbal K; Grundke-Iqbal I
Cell Mol Life Sci; 2007 Sep; 64(17):2234-44. PubMed ID: 17604997
[TBL] [Abstract][Full Text] [Related]
18. In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat.
Best JD; Jay MT; Otu F; Churcher I; Reilly M; Morentin-Gutierrez P; Pattison C; Harrison T; Shearman MS; Atack JR
J Pharmacol Exp Ther; 2006 May; 317(2):786-90. PubMed ID: 16443723
[TBL] [Abstract][Full Text] [Related]
19. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
